Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

21 avr. 2026 19h15 HE | Source: F. Hoffmann-La Roche Ltd

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple...
21 avr. 2026 11h45 HE | Source: F. Hoffmann-La Roche Ltd

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous...
21 avr. 2026 01h00 HE | Source: F. Hoffmann-La Roche Ltd

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If...